Dipyridamole/prednisolone

Drug Profile

Dipyridamole/prednisolone

Alternative Names: CRx-102; CRx-102 aligned release; Prednisolone/dipyridamole; Prednisolone/dipyridamole aligned release; Synavive AR; Z-102

Latest Information Update: 01 Aug 2016

Price : $50

At a glance

  • Originator CombinatoRx
  • Developer CombinatoRx; Zalicus
  • Class Anti-inflammatories; Antirheumatics; Corticosteroids; Glucocorticoids; Pregnadienetriols; Pyrimidines; Small molecules
  • Mechanism of Action Cyclic GMP phosphodiesterase inhibitors; Glucocorticoid receptor agonists; Immunosuppressants; Nucleoside transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Inflammation; Osteoarthritis; Periodontal disorders; Rheumatoid arthritis

Most Recent Events

  • 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
  • 15 Jul 2014 Zalicus has merged with EPIRUS Biopharmaceuticals
  • 13 Sep 2012 Discontinued - Phase-II for Rheumatoid arthritis in Romania (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top